Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Fosun Pharma to Double R&D Budget: $800 Million in 2016-2020

publication date: Jan 5, 2015
Shanghai Fosun Pharma announced an $800 million budget for R&D during the 13th Five-Year Plan (2016-2020), double its expenditure during the current five-year period. The largest investment will be a $240 million commitment for biosimilar drugs, centered on Shanghai Henlius Biotech Co., a subsidiary. Henlius will create a biopharma research center and build a GMP production facility for monoclonal antibodies. As a company, Fosun has long been an active M&A player, but the news makes clear the company is also increasing its internal development. More details....

Stock Symbols: (SHA: 600196; HK: 2196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital